SCHEMBL396971

SCHEMBL396971

CN(C)/C=C1\C(=O)N(Cc2ccccc2)c2ccccc21

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.72
HSD17B10 Q99714 2/20 0.72
MAPT P10636 12/20 0.65
APP P05067 11/20 0.65
SNCA P37840 11/20 0.65
CES1 P23141 3/20 0.59
ALDH2 P05091 1/20 0.59
CHRM1 P11229 1/20 0.59
ALDH3A1 P30838 1/20 0.59
TRPA1 O75762 1/20 0.54
ACHE P22303 1/20 0.52
LRRK2 Q5S007 1/20 0.51
PKM P14618 1/20 0.48
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KDM4E B2RXH2 1/20 0.48
HPGD P15428 1/20 0.48
RECQL P46063 1/20 0.48
CES2 O00748 1/20 0.48
BCHE P06276 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396972 1.00 ALDH1A1 (0.72) ALDH1A1HSD17B10MAPTAPPSNCA
SCHEMBL31558373 0.84 ALDH1A1 (1.00) ALDH1A1HSD17B10MAPTAPPSNCA
SCHEMBL1751537 0.81 APP (0.60) ALDH1A1MAPTAPPSNCACES1
SCHEMBL1751539 0.81 APP (0.60) ALDH1A1MAPTAPPSNCACES1
SCHEMBL12930175 0.81 MAPT (0.61) ALDH1A1HSD17B10MAPTAPPSNCA
SCHEMBL24856462 0.81 MAPT (0.64) ALDH1A1HSD17B10MAPTAPPSNCA
SCHEMBL7680137 0.79 MAPT (0.76) ALDH1A1HSD17B10MAPTAPPSNCA
SCHEMBL7680134 0.79 MAPT (0.76) ALDH1A1HSD17B10MAPTAPPSNCA
SCHEMBL10201731 0.79 MAPT (1.00) ALDH1A1MAPTAPPSNCANPSR1
SCHEMBL29033840 0.79 TRPA1 (0.66) ALDH1A1MAPTAPPSNCACES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101604-B2 Alpha carbolines and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-8101604-B2 Alpha carbolines and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-8101604-B2 Alpha carbolines and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20100311715-A1 ALPHA CARBOLINES AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-09 US disclosed
US-20100311715-A1 ALPHA CARBOLINES AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-09 US disclosed
US-20100311715-A1 ALPHA CARBOLINES AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-09 US disclosed
US-7812018-B2 inhibitors of I kappa B kinase ( IKK-2) 2-amino-9-methyl-9H-pyrido[2,3-b]indole-3-carboxamide, useful for treating inflammatory diseases and cancer MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
US-7812018-B2 inhibitors of I kappa B kinase ( IKK-2) 2-amino-9-methyl-9H-pyrido[2,3-b]indole-3-carboxamide, useful for treating inflammatory diseases and cancer MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
US-7812018-B2 inhibitors of I kappa B kinase ( IKK-2) 2-amino-9-methyl-9H-pyrido[2,3-b]indole-3-carboxamide, useful for treating inflammatory diseases and cancer MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
US-20070207997-A1 Alpha carbolines and uses thereof MILLENNIUM PHARMACEUTICALS, INC. 2007-09-06 US disclosed
US-20070207997-A1 Alpha carbolines and uses thereof MILLENNIUM PHARMACEUTICALS, INC. 2007-09-06 US disclosed
US-20070207997-A1 Alpha carbolines and uses thereof MILLENNIUM PHARMACEUTICALS, INC. 2007-09-06 US disclosed
WO-2007097981-A2 ALPHA CARBOLINES AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207997-A1 Alpha carbolines and uses thereof CHRM1, CNR1, CXCR1 ALDH1A1 416/4885HSD17B10 2729/4885MAPT 3493/4885
US-20100311715-A1 ALPHA CARBOLINES AND USES THEREOF CHRM1, CNR1, CXCR1 ALDH1A1 416/4885HSD17B10 2729/4885MAPT 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.